Additional Considerations When Treating with TECFIDERA1,2


  • The terminal half-life of the active metabolite of TECFIDERA (monomethyl fumarate (MMF)) is ~1 hour, and there are no circulating metabolites at 24 hours in the majority of individuals
  • The accumulation of MMF does not occur with multiple doses of TECFIDERA
  • TECFIDERA can be discontinued if necessary, without the need for accelerated elimination or additional agents

Drug interaction studies1

  • TECFIDERA has no known drug interactions identified from in vitro CYP inhibition and induction studies, or from P-glycoprotein studies
  • Aspirin, when administered approximately 30 minutes before TECFIDERA, did not alter the pharmacokinetics of MMF


  • Coadministration of TECFIDERA with a combined oral contraceptive (norelgestromin and ethinyl estradiol) did not elicit any relevant effects in oral contraceptives exposure
  • No interaction studies have been performed with oral contraceptives containing other progestogens


  • There are no adequate data on the developmental risk associated with the use of TECFIDERA in pregnant women
  • Instruct patients who are pregnant or plan to become pregnant while taking TECFIDERA that they should inform their healthcare professional
    • Encourage patients to enroll in the TECFIDERA Pregnancy Registry if they become pregnant while taking TECFIDERA


  • There are no data on the presence of TECFIDERA or monomethyl fumarate in human milk. The effects on the breastfed infant and on milk production are unknown